Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

801 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
Kessler C, Oldenburg J, Ettingshausen CE, Tiede A, Khair K, Négrier C, Klamroth R. Kessler C, et al. Among authors: oldenburg j. Haemophilia. 2015 Jan;21 Suppl 1:1-12. doi: 10.1111/hae.12582. Haemophilia. 2015. PMID: 25472812 Review.
Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G. Tiede A, et al. Among authors: oldenburg j. Haemophilia. 2017 Jul;23(4):547-555. doi: 10.1111/hae.13191. Epub 2017 Feb 24. Haemophilia. 2017. PMID: 28233381 Clinical Trial.
Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.
Pollmann H, Externest D, Ganser A, Eifrig B, Kreuz W, Lenk H, Pabinger I, Schramm W, Schwarz TF, Zimmermann R, Zavazava N, Oldenburg J, Klamroth R. Pollmann H, et al. Among authors: oldenburg j. Haemophilia. 2007 Mar;13(2):131-43. doi: 10.1111/j.1365-2516.2006.01416.x. Haemophilia. 2007. PMID: 17286765
Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.
Lentz SR, Cerqueira M, Janic D, Kempton C, Matytsina I, Misgav M, Oldenburg J, Ozelo M, Recht M, Rosholm A, Savic A, Suzuki T, Tiede A, Santagostino E. Lentz SR, et al. Among authors: oldenburg j. Haemophilia. 2016 Sep;22(5):e445-9. doi: 10.1111/hae.12990. Epub 2016 Jun 13. Haemophilia. 2016. PMID: 27291066 Clinical Trial. No abstract available.
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.
Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A. Iorio A, et al. Among authors: oldenburg j. Haemophilia. 2017 May;23(3):e170-e179. doi: 10.1111/hae.13215. Epub 2017 Mar 26. Haemophilia. 2017. PMID: 28345268
801 results